Christopher Wixom, M.D, Laboratory Director
Toll Free: 888.VANTAGE (888.826.8243)
Fax: 858.638.8298

VANTAGEPOINT LABORATORY PARTNERS

4980 Carroll Canyon Road
San Diego, CA 92121
client.services@vpointlabs.com

Patient Name:	Sample Patient	**Ordering Physician:**	Smith, Jane
D.O.B. & Gender:	10/10/20XX (xx yrs.) - Male	**Ordering Facility:**	John Doe Medical Group
Collection Date:	06/26/2014	**Account Number:**	0000
Received Date:	06/27/2014	**VantagePoint ID #:**	200000
Report Date:	06/27/2014	**VantagePoint Case #:**	FLG13-000000
Specimen Type:	Bone Marrow	**Medical Record #:**	

Flow Cytometry Report

Diagnosis: 1) POSITIVE FOR ACUTE MYELOID LEUKEMIA WITH 35% BLASTS DETECTED.
2) LEUKEMIA LACKS CD34 AND HLA-DR; FEATURES WORRISOME FOR ACUTE PROMYELOCYTIC LEUKEMIA SUBTYPE OF AML (PLEASE SEE INTERPRETATION).

Interpretation: The blasts percentage by flow cytometry is consistent with an acute myeloid leukemia. The lack of HLA-DR & CD34 is a phenotype which is seen in AML-M3 (a.k.a. acute promyelocytic leukemia), but can occasionally be seen post-therapy. Limited morphologic review of the smear is inconclusive in determining AML-M3 versus AML,not otherwise specified. Flourescence in-situ hybridization for translocation (15;17) - (PML/RARA gene re-arrangement), can be performed if needed (or if no previous diagnosis present). This translocation would be diagnostic for acute promyelocytic leukemia if present. Please contact Vantage Point Laboratories, if testing needed. Please also correlate with core biopsy, if available.

The aberrant CD7 and CD56 expression have utility in future detection of residual disease.

PHENOTYPE OF BLASTS:
POSITIVE FOR: CD4, CD11B, CD13, CD33, CD38, CD56, CD117, ABERRANT CD7
NEGATIVE FOR: CD34, HLA-DR

CD45 Dim: 35% blasts of with myeloid phenotype mentioned above.
Lymphocytes are unremarkable.
Monocytes: mature monocytic phenotype. Only 4%.
Granulocytes: The mature ganulocytes are decreased with variable phenotypic abnormalities.

Specimen Yield: Adequate **Viability:** Adequate

Clinical Data: xx year old male
Submitted Dx: 205.00
Additional Clinical Data Submitted: RBC 2.8 mm3; WBC 5.1 mm3; HGB 10.1 g/dL; HCT 30.6%; PLT 22 mm3

Flow Cytometry Differential (% of Total Cells)	
Lymphocytes	30%
B-cells	10%
Kappa	19%
Lambda	12%
Kappa:Lambda Ratio	1.6
T-cells	19%
CD4	30%
CD8	31%
CD4:CD8 Ratio	1.0
Monocytes	4%
Granulocytes	24%
CD45 Dim	35.0%
Viability	95%

Coexpressions	
CD19+CD5+	3%
CD19+CD10+	2%
CD4+CD8+	0%





Markers: Antibodies against the following antigens were used in comprehensive ten-color multiparameter flow cytometric Screen panel analysis: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b,CD11c CD13, CD14, CD16, CD19, CD20,CD23,CD25,CD33, CD34, CD38, CD45, CD56, CD64, CD103,CD117, HLA-DR, Kappa, Lambda, CD22, FMC-7. (29 Markers)



Electronically Signed by:

Anand Kunda M.D.
Hematopathologist

VantagePoint Laboratory Partners (CLIA ID: 05D0643041)
Christopher Wixom, M.D, Laboratory Director